SAN DIEGO, CA, USA I May 6, 2013 I La Jolla Pharmaceutical Company (OTCBB: LJPC) (“La Jolla” and “Company”), a leader in the development of therapeutics targeting galectin proteins, announced today that it has treated the last patient in the Phase 1 (Part A) portion of the Phase 1/2 clinical trial of GCS-100 in patients with chronic kidney disease (“CKD”). A total of 29 patients with Stage 3b and 4 CKD were enrolled and treated. La Jolla expects to release data from this portion of the clinical trial later this month.
“We are very pleased with the quick progress made enrolling the Phase 1 portion of the trial and believe this underscores the significant unmet medical need of CKD patients. We are evaluating the data and hope to release the results shortly,” said George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla.
The primary objectives of the study include evaluating the safety of a single dose (Part A) and repeat doses (Part B) of GCS-100. Secondary study objectives include evaluating galectin-3 serum levels, renal function, and other markers of disease activity in CKD. The study is open to patients at least 18 years of age with moderately severe to severe renal impairment. While not currently anticipated, the study design may be amended from time-to-time to comply with requests from the FDA, the governing Institutional Review Board, study investigators, or at the discretion of the Company.
About Chronic Kidney Disease
Chronic kidney disease currently affects 14% of Americans or approximately 49 million people. The United States Renal Data System, 2012 Annual Data Report, states that in 2010, costs for CKD reached $41 billion for Medicare alone. Overall per person per year costs for CKD were estimated at $22,323 for Medicare patients of age 65 and older and $13,395 for patients of age 50-64. Patients with CKD may progress to end-stage renal disease (“ESRD”). According to the National Institute of Diabetes and Digestive and Kidney Diseases as of 2008, there were 547,982 individuals in the US under treatment for ESRD and 88,630 deaths per year from ESRD.
About GCS-100
GCS-100 is a complex polysaccharide that has the ability to bind to and block the effects of galectin-3. Galectin-3 is a soluble protein, over-expression of which has been implicated in a number of human diseases including cancer and chronic organ failure. The unique ability of GCS-100 to bind and sequester galectin-3 makes it an ideal candidate to prevent and treat diseases in which galectin-3 plays an important role.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company’s lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. For more information on the Company please visit http://www.ljpc.com.
SOURCE: La Jolla Pharmaceuticals
Post Views: 159
SAN DIEGO, CA, USA I May 6, 2013 I La Jolla Pharmaceutical Company (OTCBB: LJPC) (“La Jolla” and “Company”), a leader in the development of therapeutics targeting galectin proteins, announced today that it has treated the last patient in the Phase 1 (Part A) portion of the Phase 1/2 clinical trial of GCS-100 in patients with chronic kidney disease (“CKD”). A total of 29 patients with Stage 3b and 4 CKD were enrolled and treated. La Jolla expects to release data from this portion of the clinical trial later this month.
“We are very pleased with the quick progress made enrolling the Phase 1 portion of the trial and believe this underscores the significant unmet medical need of CKD patients. We are evaluating the data and hope to release the results shortly,” said George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla.
The primary objectives of the study include evaluating the safety of a single dose (Part A) and repeat doses (Part B) of GCS-100. Secondary study objectives include evaluating galectin-3 serum levels, renal function, and other markers of disease activity in CKD. The study is open to patients at least 18 years of age with moderately severe to severe renal impairment. While not currently anticipated, the study design may be amended from time-to-time to comply with requests from the FDA, the governing Institutional Review Board, study investigators, or at the discretion of the Company.
About Chronic Kidney Disease
Chronic kidney disease currently affects 14% of Americans or approximately 49 million people. The United States Renal Data System, 2012 Annual Data Report, states that in 2010, costs for CKD reached $41 billion for Medicare alone. Overall per person per year costs for CKD were estimated at $22,323 for Medicare patients of age 65 and older and $13,395 for patients of age 50-64. Patients with CKD may progress to end-stage renal disease (“ESRD”). According to the National Institute of Diabetes and Digestive and Kidney Diseases as of 2008, there were 547,982 individuals in the US under treatment for ESRD and 88,630 deaths per year from ESRD.
About GCS-100
GCS-100 is a complex polysaccharide that has the ability to bind to and block the effects of galectin-3. Galectin-3 is a soluble protein, over-expression of which has been implicated in a number of human diseases including cancer and chronic organ failure. The unique ability of GCS-100 to bind and sequester galectin-3 makes it an ideal candidate to prevent and treat diseases in which galectin-3 plays an important role.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company’s lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. For more information on the Company please visit http://www.ljpc.com.
SOURCE: La Jolla Pharmaceuticals
Post Views: 159
